This multinational real-world study confirms that ON101 has broad effectiveness even in difficult to manage subgroups (e.g., patients with high HbA1C, large ulcers or plantar ulcers, etc.), with the following positive results:
Conclusion
ON101 demonstrated high healing rates, faster wound resolution, and excellent safety in the treatment of DFUs across varied healthcare settings. The reduced number of clinic visits highlight ON101’s clinical and economic value. These findings support ON101 as a promising global option for DFU management and re-admission prevention.
Diabetic foot ulcers (DFUs) are among the most serious complications of diabetes, often associated with delayed healing, infection, high rate of limb loss, and frequent hospital re-admissions. ON101 is a topical medical device formulated to support wound healing by promoting fast painless tissue healing process in a adequate wound environment. This multinational, real-world study assessed ON101’s clinical effectiveness , safety and lower morbidity and frequency of hospital re-admissions across diverse healthcare settings in the United States, India, and Egypt.